Alyeska Investment Group, L.P. Nuvalent, Inc. Transaction History
Alyeska Investment Group, L.P.
- $23.4 Billion
- Q1 2025
A detailed history of Alyeska Investment Group, L.P. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 51,303 shares of NUVL stock, worth $3.92 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
51,303
Previous 102,605
50.0%
Holding current value
$3.92 Million
Previous $8.03 Million
54.7%
% of portfolio
0.02%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding NUVL
# of Institutions
216Shares Held
60.9MCall Options Held
319KPut Options Held
211K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.37 Billion32.3% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.27MShares$402 Million19.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$339 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$231 Million0.01% of portfolio
-
Commodore Capital LP New York, NY1.86MShares$142 Million12.88% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.28B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...